




RECOMMEND WITH CERTAINTY— SHINGRIX IS NOW \$0 FOR NEARLY ALL PATIENTS 50 YEARS AND OLDER¹⁻³


For your patients with commercial insurance plans



More than 9 out of 10 are covered*:

- Average copays are just \$4 or less¹
- 95% of commercial patients pay \$0 for SHINGRIX^{1,3}

For your Medicare Part D patients



Great coverage is now even better*:

Starting January 2023, due to the Inflation Reduction Act, all Medicare Part D patients can now get SHINGRIX for \$0 through their pharmacy.¹⁻³

*SOURCE: Managed Markets Insight & Technology, LLC, Database as of October 2022. Coverage represents access to reimbursement from a health plan with restrictions appropriate to the Advisory Committee on Immunization Practices (ACIP) recommendation(s) and/or prescribing information. Veterans Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives.^{1,3}

INDICATION

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

IMPORTANT SAFETY INFORMATION

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Please see additional Important Safety Information on the back and accompanying full Prescribing Information, also available at [SHINGRIXHCP.com](https://www.shingrixhcp.com)

SHINGRIX IS NOW \$0 FOR NEARLY ALL PATIENTS 50 YEARS AND OLDER¹⁻³

IMPORTANT SAFETY INFORMATION (CONT'D)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information on the front and accompanying full [Prescribing Information](#), also available at [SHINGRIXHCP.com](#)

Learn more at [SHINGRIXHCP.COM](#)

References: 1. Data on file, GSK. 2. Kirchoff SM. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022; 1-3. Accessed November 16, 2022. <https://crsreports.congress.gov/product/pdf/IF/IF12203> 3. Managed Markets Insight & Technology, LLC, Database as of October 2022.

Trademarks are owned by or licensed to the GSK group of companies.



©2022 GSK or licensor.
SGXLBND220020 December 2022
Produced in USA. 0002-0021-31



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)